Fig. 2

Time course of DAS28-ESR and EULAR responses. A Changes in disease activity categories according to DAS28-ESR are shown at baseline, 4, 12, and 24 weeks after the treatment with tofacitinib or abatacept. B The proportion of patients meeting the EULAR response criteria are shown 4, 12, and 24 weeks after the start of treatment with tofacitinib or abatacept. The percentage of patients who achieved good or moderate EULAR responses or DAS28-ESR remission were compared between the two treatment groups at each time point. DAS28-ESR, Disease Activity Score in 28 joints using the erythrocyte sedimentation rate; EULAR, European League Against Rheumatism